) announced the completion of the acquisition of Prague-based
Unimedis, a distributor of equipment for the treatment of sleep
disordered-breathing in the Czech Republic and Slovakia. The
terms of the deal remain undisclosed.
Per the deal, Unimedis will continue to cater to the entire Czech
and Slovak markets under the ResMed banner, guided by country
manager, Ondrej Kalas.
Sleep-disordered breathing (SDB) affects around 20% of the global
adult population. Nonetheless, it is still a niche market segment
in the healthcare industry, primarily due to low awareness
ResMed plans to spread its wings in emerging markets, mostly
through acquisitions. This inorganic growth strategy will help it
to exploit opportunities in markets with greater potential.
ResMed further believes that such a strategy will enable them to
serve their customers in far reaching countries, with better
sleep-disordered breathing and respiratory care solutions.
This acquisition is part of ResMed's consolidated attempts to
expand its core business of sleep-disordered breathing products.
The company is also considering the inorganic growth path for its
fast-evolving Respiratory Care and Cardio-respiratory businesses.
The Czech Republic is primarily in focus with the country's
health care policy undergoing a transformation, laying greater
value on compliance and outcomes of reimbursed therapies. This
fits in well with ResMed's solutions to enhance compliance and
facilitate remote compliance management to improve quality and
efficiency of patient care.
The foray into the Czech and Slovak markets should also be
accretive to the growing portfolio of ResMed's respiratory care
and cardiology solutions. The company has also recently acquired
Warsaw-based Mediserv, now known as ResMed-Poland.
On the other hand, Unimedis expects to benefit from the ResMed
brand name, and continue to offer consistent and quality service
and products to its customers.
Currently, ResMed carries a Zacks Rank #3 (Hold). However,
investors interested in the industry can consider stocks like
Hill-Rom Holdings, Inc.
). While Hill-Rom Holdings and NuVasive sport a Zacks Rank #1
(Strong Buy), Chimerix carries a Zacks Rank #2 (Buy).
CHIMERIX INC (CMRX): Free Stock Analysis
HILL-ROM HLDGS (HRC): Free Stock Analysis
NUVASIVE INC (NUVA): Free Stock Analysis
RESMED INC (RMD): Free Stock Analysis Report
To read this article on Zacks.com click here.